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Background: Florbetapir (AV-45) has been shown to be a reliable tool to assess amyloid load in patients with
Alzheimer's disease (AD) at demential stages. Longitudinal studies also suggest that AV-45 has the ability to bind amyloid
in the early stages of AD. In this study, we investigated AV-45 binding and its relation with cognitive performance in a
group of patients at the prodromal stage of Alzheimer's disease, recruited according to strict inclusion criteria.
Methods: We recruited patients at the prodromal stage of AD and matched control subjects. AV-45 binding was
assessed using an innovative extraction method allowing quantifying uptake in the cortex only. AV-45 uptake was
compared between groups in the precuneus, posterior cingulate, anterior cingulate, and orbito-frontal regions.
Correlations between AV-45 uptake and cognitive performance were assessed.
Results: Twenty-two patients and 17 matched control subjects were included in the study. We report a significant
increase of cortical AV-45 uptake in the patients compared to the control subjects in all regions of interest. Specific
correlations were found within the patient group between mean global amyloid cortical load and cognitive performance
in three different memory tests.
Conclusions: These findings suggest that at the prodromal stage of AD, memory decline is linked to an increase of
cortical β-amyloid load.
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In the past decade, it has been recognized that Alzheimer's
disease (AD) has a clinical stage before dementia occurs, a
stage now known as prodromal. The diagnosis of pro-
dromal AD according to research criteria [1,2] relies on an
objective cognitive impairment, most often a memory de-
cline, as assessed by a neuropsychological evaluation, and
one or more of the following specific features: medial
temporal lobe atrophy on structural magnetic reso-
nance imaging (MRI), temporo-parietal hypometabolism
on positron-emission tomography (PET) scan using* Correspondence: laure.saint-aubert@inserm.fr
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reproduction in any medium, provided the orig18F-fluorodeoxyglucose (FDG), or markers of amyloid
pathology. As recently published in the new AD and mild
cognitive impairment (MCI) criteria, amyloid biomarkers
tend to have an increased weight in the diagnosis [3,4].
Hence, amyloid biomarkers are nowadays embedded in
the diagnostic criteria, not only for AD-related dementia,
but also for the prodromal stage of AD (see Dubois et al.
[2]). Several studies have shown that the use of amyloid
biomarkers may drastically modify the accuracy of AD
diagnosis. In these studies, in vivo amyloid pathology is
assessed using cerebrospinal fluid (CSF) or through spe-
cific ligands by PET imaging. CSF amyloid-beta (Aβ) bio-
markers have now been widely studied [5]. New ratios
between Aβ42, Aβ40, tau, and phospho-tau and the use of
new concentration cutoffs [5,6] appear to be reliable tools
to detect AD at an early stage [7]. Numerous studies have
been conducted using PET to bind amyloid plaques
in vivo [8,9]. 18F-florbetapir (AV-45) ligand showsis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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to control subjects [10,11]. AV-45 shows good correlations
with post-mortem lesions [12,13]. AV-45 has shown good
consistency with clinical examination in patients having
the genetic forms of AD [14,15] as well as in sporadic
forms at the demential stage [11]. A few studies have
assessed AV-45 uptake in patients with MCI [10,16-18].
Fleisher et al. showed a significant increase of AV-45 up-
take in MCI compared to healthy subjects [10].
Doraiswamy et al. reported that MCI patients with visually
positive AV-45 images showed clinical worsening and
tended to convert to dementia at a higher rate [16]. How-
ever, MCI patients may have pathologies other than AD or
even no pathology at all. Florbetapir has never been stud-
ied in a population of prodromal AD patients who were
characterized according to research criteria [1].
A problem regarding AV-45 binding is that it is sug-
gested to bind in a non-specific manner to the white mat-
ter [12]. Up to now, only a few studies have attempted to
deal with this issue using masking techniques [19,20].
These studies showed that more methodological develop-
ments are required.
AV-45 binding is also related to lower episodic mem-
ory performance in clinically normal older individuals
[21]. So far, no correlation has been reported between
cognitive performance and AV-45 uptake in AD patients
at the prodromal stage.
In this study, our aim was to investigate the profile of
cortical AV-45 binding, using a new method, and its re-
lation to cognitive performance in a group of AD pa-
tients at the prodromal stage recruited according to
strict inclusion criteria in comparison with a group of
matched cognitively normal subjects.
Methods
Participants
All participants gave their written informed consent.
This study was approved by the local ethics committee
(Comité de Protection des Personnes Sud-Ouest et
Outre-Mer I) and the French Agency for Safety and Se-
curity of Medical Devices (Agence Française de Sécurité
Sanitaire des Produits de Santé, reference A90605-58).
For this study, patients at the prodromal stage of AD
[2] over 65 years old were recruited. They all came from
the outpatient memory clinic (Neurology Department,
University Hospital, Toulouse, France). Matched control
subjects were recruited among patients' relatives or by
recruitment posting in public places.
Pre-inclusion assessment
Patients were invited to enroll in the study if they
presented a memory complaint dating from more than 6
months, had no concomitant neurologic or psychiatric
disease history, and were not affected by any clinicallysignificant pathology that could explain their memory
complaint. Patients then underwent the following:
 Pre-inclusion neuropsychological assessment:
Autonomy in daily life was assessed using the
Clinical Dementia Rating (CDR) scale. Anterograde
verbal memory was assessed using the Free and
Cued Selective Reminding Test (FCSRT) [22].
 Brain MRI: Brain MRI was performed in all
participants using a Philips 3-T imager (Intera
Achieva, Philips, Best, The Netherlands). A high-
resolution anatomical image, using a three-
dimensional (3D) T1-weighted sequence (in-plane
resolution 1 × 1 mm, slice thickness 1 mm, 160
contiguous slices) and a T2-weighted sequence
(reconstructed resolution 0.45 × 0.45 × 3 mm3, 43
slices) were obtained. Two independent
neuroradiologists with extensive experience (FB and
RG), blind to clinical information, examined all
sequences at inclusion and rated them for both
medial temporal lobe atrophy on the 3D T1
sequence using the Scheltens scale [23] and white
matter changes on the T2-weighted images using
the Fazekas and Schmidt (F&S) scale [24]. Atrophy
was assessed for the two hemispheres separately.
Inter-rater agreement was estimated by calculating
Cohen's kappa coefficient (κ) and its 95% confidence
interval (CI).
 FDG-PET scan: Scans were performed on a Biograph
6 TruePoint Hirez (Siemens Medical Solutions,
Munich, Germany) hybrid PET/computed
tomography (CT) scanner (3D detection mode,
producing images with 1 × 1 × 1.5 mm voxels and a
spatial resolution of approximately 5 mm full width
at half maximum at the field of view center).
Cerebral emission scans began 20 min after the
injection of 1.85 MBq/kg weight of FDG on average
and lasted for 10 min. Both CT and PET scans were
acquired. PET data were corrected for partial
volume effects. Two independent nuclear medicine
physicians with extensive experience in reading
FDG-PET scans (PiP and AH), blind to clinical
information, examined all FDG-PET scans at
inclusion. A three-point scale was used for rating
FDG-PET profiles (0 = normal, 1 = temporo-parietal
hypometabolism suggestive of AD, 2 = other). Inter-
rater agreement was estimated by calculating κ and
its 95% CI.
 CSF biomarker sampling: CSF samples were
obtained by a lumbar puncture in the patient group.
The samples were centrifuged for 10 min at 1,500
rpm at 4°C to remove cells, aliquoted to 0.4-mL
samples in polypropylene tubes, and stored at −80°C
until analysis. CSF biomarker levels of total tau (T-
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measured using a sandwich ELISA method
(Innogenetics, Gent, Belgium) according to the
manufacturer's instructions. We also calculated ratios
derived from single biomarkers, including the Innotest
Amyloid Tau Index (IATI), combining Aβ42 and T-
Tau concentrations as follows: IATI = Aβ42 / (240 +
(1.18 × T-Tau)), and the Aβ42/Aβ40 ratio.
Control subjects underwent the same neuropsycho-
logical assessment, MRI, and FDG-PET scans as the
patients.
Inclusion criteria
Following these examinations, patients were given the
diagnosis of prodromal AD [2] and included in the present
study if they met the following criteria: CDR = 0.5, sum of
the three free recalls ≤17/48, and/or sum of the three free
and cued recalls ≤40/48 on the FCSRT [25], and one or
more of the following features:
 Scheltens score for medial temporal lobe atrophy >1
in at least one hemisphere for at least one visual
rater [23].
 Temporo-parietal hypometabolism pattern on
cerebral FDG-PET scan (score = 1 for at least one
visual rater).
 P-Tau ≥ 60 pg/mL and IATI ≤ 0.8. In the case of an
‘ambiguous’ profile (P-Tau < 60 pg/mL or IATI >
0.8), Aβ42/Aβ40 was calculated and a score < 0.045
was considered as compatible with AD diagnosis
[6,26].
 Patients with significant white matter T2
hyperintensities (F&S score > 2 for at least one
visual rater) were excluded.
Control subjects were included if they had no memory
complaint, no neurological or psychiatric disease history, or
no first-degree relatives with AD. They were excluded if they
showed significant white matter hyperintensities on their
T2-weighted MR images (F&S score > 2 for at least one vis-
ual rater) or any cognitive impairment on the pre- or post-
inclusion neuropsychological assessment (test scores below
−2 standard deviations according to the norms).
Patients and control subjects were then assessed with
detailed neuropsychological evaluation and AV-45-PET.
Post-inclusion assessment
Neuropsychological assessment
A comprehensive battery of tests was used for all partici-
pants. Global cognitive state was assessed using the
Mini-Mental State Examination (MMSE), while the 4-
Instrumental Activities of Daily Living test was used to
assess daily-life autonomy. The following cognitivedomains were assessed: visual memory (Rey-Osterrieth
Complex Figure Test (RCFT) [27], DMS48 [28]), seman-
tic memory (Weschler Adult Intelligence Scale (WAIS)
information subtest [27], TOP 12 faces [29]), verbal
working memory (WAIS-III digit span [27]), praxies
(RCFT copy, praxies evaluation protocol [30]), language
(DO80 - a French confrontation naming test [31]), ex-
ecutive functions (phonemic and semantic verbal flu-
encies [27], Trail Making Test (TMT) [27], Frontal
Assessment Battery (FAB) [32], Stroop [27]), gnosia
(Benton Facial Recognition Test [27]), and attention
(TMT, Symbol Digit Modalities Test [27]). Anxiety and
depression were also assessed using the State-Trait Anx-
iety Inventory (Y-A form) [33] and Beck Depression In-
ventory [27], respectively.
AV-45-PET scan
All participants underwent a second PET scan using the
AV-45 amyloid marker. Scans were performed on the
same PET/CT scanner as for FDG-PET, using identical re-
construction parameters. Cerebral emission scans began
50 min after an injection of 3.7 MBq/kg weight of AV-45
and lasted for 20 min. Both CT and PET scans were ac-
quired. PET data were corrected for partial volume effects.
ApoE alleles
This analysis was performed using blood samples from
the patient group only. All these examinations were
spread over three different appointments, scheduled
within 3 months maximum.
Statistical analysis
Neuropsychological assessment
Intergroup comparisons were performed using the Mann–
Whitney statistical test.
MRI
Cortical morphology differences between the two groups
were assessed using a voxel-based morphometry (VBM)
method on Statistical Parametric Mapping version 8
(SPM8; Wellcome Trust Centre for Neuroimaging,
London, UK) software running on MATLAB (Mathworks
Inc., Sherborn, MA, USA). For each subject, 3D T1 se-
quence was normalized to the SPM8 template, then seg-
mented to isolate gray matter and white matter partitions,
and modulated for deformations. The resulting modulated
gray matter maps were then smoothed (8 × 8 × 8 mm)
and pooled by group for statistical inter-group comparison
using voxel-based analysis (threshold for significance
p < .001, uncorrected; cluster = 20 voxels).
FDG- and AV-45-PET global uptake
For both ligands, uptake differences between groups
were assessed using a voxel-based analysis on SPM8








n 22 17 NA
Age 72.4 ± 5.0 69.9 ± 4.8 .110
Gender 12 M/10 F 7 M/10 F .408
Level of education 11.3 ± 2.7 12.8 ± 3.3 .163
Disease duration 3.8 ± 3.6 NA NA





CDR scale 0.5 ± 0.0 0.0 ± 0.0 <.001*
Anterograde verbal memory
FCSRT sum of free recalls (/48) 11.6 ± 5.9 32.2 ± 4.6 <.001*
FCSRT sum of free + cued recalls (/48) 28.7 ± 11.9 46.6 ± 1.9 <.001*
Global cognitive state
MMSE 25.7 ± 1.4 28.4 ± 0.7 <.001*
Depression scale
Beck (/39) 3.0 ± 2.6 2.7 ± 2.6 .666
Anxiety scale
Y-A (/80) 34.3 ± 8.9 3.2 ± 6.0 .830
Anterograde visual memory
DMS48 set 1 (/48) 41.0 ± 6.0 46.5 ± 2.0 .003*
DMS48 set 2 (/48) 40.0 ± 7.0 45.9 ± 2.2 .014*
Rey complex figure memory (/36) 9.2 ± 6.6 19.4 ± 6.1 .002*
Semantic memory
Information subtest (WAIS) (/28) 13.8 ± 5.5 20.1 ± 6.2 .014*
TOP 12 faces version: global score (/96) 74.8 ± 6.7 84.6 ± 6.0 .003*
TOP 12 faces version: naming (/12) 5.2 ± 3.4 9.3 ± 2.2 .006*
Short-term memory
WAIS-III digit span: forward 5.6 ± 1.4 5.4 ± 1.0 1.763
Working memory
WAIS-III digit span: backward 4.0 ± 1.2 4.6 ± 0.9 .514
Language
DO80 (/80) 78.1 ± 3.8 79.4 ± 1.2 .549
Praxies
Rey complex figure copy (/36) 34.4 ± 1.9 34.6 ± 2.0 1.258
Speed processing
Digit-symbol test (/90) 34.1 ± 12.6 52.8 ± 10.2 <.001*
Executive functions
Phonemic verbal fluency: letter (P) 19.6 ± 8.1 22.6 ± 6.1 .674
Semantic verbal fluency: ‘animal’ category 21.7 ± 7.3 31.8 ± 7.4 .012*
TMT B time 170.3 ± 85.3 94.1 ± 38.4 .014*
Interference time on the Stroop test 108.1 ± 45.1 51.6 ± 31.9 .002*
FAB (/18) 15.1 ± 2.5 17.1 ± 0.8 .098
Table 1 Population description and performance at
neuropsychological assessment (Continued)
Gnosia
Benton Facial Recognition (/58) 46.0 ± 3.3 48.1 ± 3.5 .476
CDR scale, Clinical Dementia Rating scale; FCSRT, Free and Cued Selective
Recall Reminding Test; NA, not applicable. *p < .05 (significant difference on
the Mann–Whitney test).
Saint-Aubert et al. EJNMMI Research 2013, 3:43 Page 4 of 9
http://www.ejnmmires.com/content/3/1/43(threshold for significance p < .001, uncorrected; cluster
= 20 voxels). FDG-PET scans were whole-brain-normal-
ized using a PET template from SPM8, smoothed (8 × 8
× 8 mm), and pooled by group for statistical comparison.
AV-45-PET scans were whole-brain-normalized using a
template from Avid [34], smoothed (8 × 8 × 8 mm), and
pooled by group for statistical comparison.
AV-45 regional uptake values in the cortex only
Due to AV-45 non-specific binding reported in the white
matter [11], regional mean standardized uptake values
(SUVs) were calculated from the cortex only as follows:
For each subject, CT scan obtained during AV-45-PET ac-
quisition was first linearly registered onto the MRI ana-
tomical T1 image using FSL software. The obtained
transformation matrix was then applied to the AV-45
image of the subject so that AV-45 image was in the T1
space. Gray matter mask from T1 segmentation (see MRI
statistical analysis) was binarized using a 0.3 threshold and
applied to the AV-45 image. An Anatomical Automatic
Labeling [35] template was also registered onto each indi-
vidual T1 space using the inverse of the transformation
matrix obtained, registering the individual T1 onto the
Montreal Neurological Institute (MNI) space. Then mea-
sures of regional cortical AV-45 mean SUV were
conducted for each subject using an in-house MATLAB
script. Mean global cortical SUV was calculated as well as
SUV from specific regions of interest (ROIs): orbito-
frontal, anterior cingulate, posterior cingulate, and
precuneus. These regions were selected as they have
shown different AV-45 binding in studies comparing AD
patients to control subjects [9-11,36]. SUVs were then
normalized (SUVr) to whole cerebellar mean uptake
(vermis excluded) and pooled by group for statistical com-
parison. Inter-group regional uptake difference was
assessed using a non-parametric Mann–Whitney statis-
tical test (threshold for significance p < .05), and the
Bonferroni-Holmes correction for multiple comparisons
was applied.
AV-45 SUVr correlation analyses
Correlations were investigated in the patient group be-
tween mean global cortical AV-45 SUVr and cognitive
performance scores at memory tests: delayed free recall
and delayed total recall subtests of the FCSRT [22] (ver-
bal anterograde memory), recall of the RCFT [27] (visual
Figure 1 AV-45-PET imaging uptake. Regional-to-cerebellum
standard uptake values (SUVr) for AV-45 marker in the global cortex
(left side of the vertical line) and specific regions of interest (right
side of the vertical line) are shown with associated standard
deviations. Red diamonds, patients; green diamonds, control
subjects. **p < .01 (significant inter-group difference on the
Mann–Whitney test, Bonferroni-Holmes-corrected).







Global cortex 1.43 (±.29) 1.15 (±.08) .002**
Orbito-frontal 1.60 (±.41) 1.23 (±.16) .001**
Anterior cingulate 1.67 (±.41) 1.30 (±.16) .003**
Posterior cingulate 1.74 (±.36) 1.36 (±.14) .002**
Precuneus 1.56 (±.36) 1.14 (±.09) .002**
AV-45 mean regional-to-cerebellum standard uptake values (SUVr) with
associated standard deviation (sd) are mentioned for the global cortex and
specific regions of interest for the two groups. **p < .01 (significant inter-
group difference on the Mann–Whitney test, Bonferroni-Holmes-corrected).
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memory), the WAIS information subtest (semantic
memory), the naming score, and the total score at the
TOP 12 [29] (an innovative test assessing semantic
memory about the life of 12 celebrities from their face).
Correlations between relevant AV-45 SUVr and CSF
marker concentrations were also investigated in patients.
The Spearman non-parametrical test was used (thresh-
old for significance p < .05).
Results
A total of 34 patients and 25 control subjects enrolled in
the study. Among them, 22 patients and 17 control sub-
jects satisfied the inclusion criteria and completed the
whole protocol. There was no significant difference in
age, sex, or level of education between the patients and
the control groups (Table 1).
Fulfillment of the inclusion criteria for prodromal AD
On imaging data, MRI visual assessment revealed tem-
poral atrophy (Scheltens score > 1) in 17 patients out of
22 (left hippocampus atrophy: κ = 0.465 with CI 0.15 to
0.78, right hippocampus atrophy: κ = 0.767 with CI 0.46
to 1.0). Visual assessment of FDG-PET scans revealed
temporo-parietal hypometabolism in 14 patients out of
22 (κ = 1). Of the 22 patients, 20 had a lumbar puncture
for CSF biomarkers; the two remaining patients did not
give their consent for CSF sampling. Eighteen of the 20
patients showed a pathological CSF profile. One was
classified as normal, and one was considered ambiguous,
with P-Tau < 60 pg/mL despite IATI ≤ 0.8 (no values
available for Aβ40 concentration for this patient; details
on individual profiles are available in Additional file 1).
When the neuropsychological assessment, MRI, FDG,
and CSF profiles were combined, 3 patients had two
markers in favor of prodromal AD, 11 had three markers,
and 8 had all four markers consistent with prodromal AD.
Inter-group comparisons of the inclusion data
Neuropsychological assessment
Patients showed significant memory and executive function
impairment compared to the control group. No significant
deficit was reported regarding other cognitive fields. Pa-
tients were neither depressed nor anxious (Table 1).
MRI
Compared to the control group, patients showed signifi-
cant atrophy, mainly in the hippocampal regions but also
in the frontal and parietal regions, on VBM analysis
(p < .001, uncorrected; Additional file 2A).
FDG-PET
The analysis was carried out between 22 patients and 16
control subjects. One control subject was excluded fromthe analysis due to unusable scan data. On voxel-based
analysis, the patient group revealed a large hypometa-
bolism in the parietal and also the temporal and frontal
lobes compared to the control group (p < .001, uncor-
rected; Additional file 2B).
AV-45 imaging
Whole brain profile of AV-45 binding
On voxel-based whole brain analysis, the patient group
showed higher AV-45 uptake in the precuneus compared
to the control group (p < .001, uncorrected; Additional
file 2C).
Regional profile of AV-45 binding
SUVr analysis in gray matter ROIs showed a significant AV-
45 increased uptake in the patient group compared to the
control group in the global cortex as well as in the
precuneus, anterior and posterior cingulate, and orbito-
frontal regions (Figure 1; mean values are shown in Table 2).
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Performance on the delayed free recall (r = −.504,
p = .017) and delayed total recall (r = −.553, p = .008)
subtests of the FCSRT as well as the naming score at the
TOP 12 semantic test (r = −.616, p = .002) correlated
negatively with global SUVr (Figure 2). Of note, AV-45
uptake did not correlate with age, and no correlations
were found between AV-45 uptake and CSF concentra-
tions in the patient group.
Discussion
In this study, we used selective criteria to recruit patients
presenting with prodromal AD [2]. Despite having fully
preserved autonomy, they showed cognitive impairment,
brain atrophy, and hypometabolism typical of AD com-
pared to control subjects as well as CSF profile typical of
AD. Nineteen of the 22 patients showed a typical profile
of AD on at least three of these four markers. Patients
consistently showed increased AV-45 uptake compared to
control subjects on both whole brain analysis and cortical
analysis using regions of interest. In the group of patients,
we also identified significant correlations between cortical
AV-45 uptake and memory performance. To our know-
ledge, the present study is the first to assess AV-45 cortical
uptake in a population of prodromal AD patients [2].
Profile of cerebral AV-45 uptake
The AV-45 PET marker has been shown to reliably as-
sess cerebral amyloid load in patients with AD [37],Figure 2 Correlation between mean global cortical AV-45 standardize
delayed free recall of the FCSRT (max = 16), (B) the delayed total recall of t
semantic test (max = 12).showing an increased uptake in AD patients, most reli-
ably reported in frontal and parietal regions [12]. Con-
sistently, we found increased cortical uptake in our
patients in the whole cortex as well as in specific regions
of interest: the orbitofrontal lobe, the anterior and pos-
terior cingulate, and the precuneus, in agreement with
previous studies [10,11,19]. Similar binding patterns have
been shown in numerous studies on MCI patients using
the 11C-PiB amyloid biomarker [38,39].
AV-45 specificity
AV-45 has been reported as showing non-specific bind-
ing in the white matter. In a recent study comparing
AV-45 and PiB fixation in AD patients at the demential
stage, Wolk et al. reported greater overlaps in uptake be-
tween AD and control groups with AV-45 than with PiB
[9]. The authors proposed that AV-45 ROI SUVr in-
cluded local non-specific white matter uptake, reducing
the specificity of the findings compared to PiB in pa-
tients. To avoid such issue, our AV-45 images were
masked to exclude non-gray matter voxels from the ana-
lyses. To our knowledge, only two other studies using
AV-45 considered the gray matter only [19,20]. Rodrigue
et al. used AV-45 images of young subjects as white mat-
ter masks for their elderly subjects [20]. In a recent
study, La Joie et al. excluded the white matter from the
analysis using a unique mask applied on normalized im-
ages in the MNI space for all participants [19]. In the
present study, we developed an optimized method tod uptake value ratio (SUVr) and memory performance. At (A) the
he FCSRT (max = 16), and (C) the naming subtest of the TOP 12
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subject's MRI white matter segmentation as a mask on
their respective AV-45 image. Our results thus apply to
AV-45 binding in the cortex only.
Relation between AV-45 uptake and cognitive
performance
In this work, we focused on the correlation between AV-45
uptake in ROIs and memory performance in the patient
group. A correlation was found with cognitive performance
in memory tests assessing verbal, visual, and semantic
memory. These results imply that memory performance
declines as the cerebral β-amyloid load increases. Different
authors have suggested that the amyloid load would reach
a plateau at the onset of the symptomatic stage [40,41]. Ac-
cordingly, no correlation should be expected with cognitive
performance. However, we did identify correlations with
memory performance, as did one recent study using AV-45
[16] and another using PiB [42], both in MCI patients.
Longitudinal studies assessing PiB binding in MCI reported
a cognitive decline along with an increase ligand uptake
[43,44]. Overall, this suggests that the amyloid load may
reach its maximum at a more variable stage of the disease
than usually reported, an idea deserving further consider-
ation. We did not find a correlation between AV-45 uptake
and CSF in patients, in contrast to other PiB studies [45].
This is possibly due to the fact that patients were partly se-
lected according to their pathological CSF profile.
Conclusions
This study on prodromal AD patients recruited
according to strict inclusion criteria revealed, using an
optimized method of quantification on the cortex only,
increased cortical amyloid load compared to cognitively
normal subjects. The amyloid load correlated with memory
decline. The AV-45 marker appears to be a promising tool
for the early, pre-demential diagnosis of AD, in particular
when focusing the analyses on gray matter uptake.
Additional files
Additional file 1: Individual profiles of patients on inclusion criteria
and mean global target-to-cerebellum Standard Uptake Values
(SUVr) for both groups. ‘+’ refers to the fulfillment of the criterion, and
‘-’ refers to the absence of abnormality on assessment. NA = not
available. ‘ambiguous’ refers to CSF biomarkers missing the Aβ40
concentration to help determine the CSF profile.
Additional file 2: Inter-group imaging analyses. Threshold for
significance p < .001 (uncorrected). A. Cerebral atrophy of patients
compared to controls. B. Hypometabolism in patients compared to
controls. C. Increased AV-45 uptake in patients compared to controls.
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